Shared and differential cortical functional abnormalities associated with inhibitory control in patients with schizophrenia and bipolar disorder

Noa Tsujii, Wakako Mikawa, Toru Adachi, Tomoyuki Hirose & Osamu Shirakawa

Schizophrenia (SZ) and bipolar I disorder (BD-I) share genetic risk factors and cognitive impairments, but these conditions may exhibit differences in cortical functioning associated with inhibitory control. We measured hemodynamic responses during a stop-signal task using near-infrared spectroscopy (NIRS) in 20 patients with SZ, 21 patients with BD-I and 18 healthy controls (HCs). We used stop-signal reaction time (SSRT) to estimate behavioural inhibition. Compared with HCs, patients with either SZ or BD-I exhibited significantly reduced activation in the bilateral inferior, middle and superior frontal gyri. Furthermore, patients with BD-I showed inactivation of the right superior temporal gyri compared with patients with SZ or HCs. Patients with SZ or BD-I demonstrated significant negative correlations between SSRT and hemodynamic responses of the right inferior frontal gyrus. Moreover, patients with SZ exhibited correlations in the middle and superior frontal gyri. Our findings suggest that right inferior frontal abnormalities mediate behavioural inhibition impairments in individuals with SZ or BD-I. Differential patterns of orbitofrontal or superior temporal functional abnormalities may reflect important differences in psychopathological features between these disorders.

Although the traditional diagnostic classification in psychiatry cuts across the natural boundaries between schizophrenia (SZ) and bipolar I disorder (BD-I), recent epidemiological and molecular evidence supports shared genetic contributions between these disorders. In addition, these psychiatric disorders share cognitive impairments that may be linked to structural and functional alterations in the frontotemporal cortex. Deficits in inhibitory control, a major component of executive function, have been described in both SZ and BD-I. Inhibitory control is the ability to override, interrupt, or abort ongoing processes, especially when these processes are well engrained. The stop-signal task can estimate the time required by an individual to withhold ongoing responses, as measured by stop-signal reaction time (SSRT). Compared with healthy controls (HCs), SSRTs are longer (i.e., suggesting impaired behavioural inhibition) in individuals with SZ or BD-I.

Neuroimaging studies indicate that inhibitory processes involve the frontal cortex, particularly the right inferior frontal gyrus and presupplementary motor area. Previous neuroimaging studies have found structural and functional abnormalities in these regions in individuals with SZ or BD-I. In addition, functional magnetic resonance imaging (fMRI) studies have reported associations between behavioural inhibition and functional abnormalities of these brain regions in individuals with SZ or BD-I. These neuroimaging studies suggest overlapping neural abnormalities in inhibitory processes between SZ or BD-I; however, it remains unclear to what extent these abnormalities have similar profiles or to what degree they differ between the two psychiatric disorders.

Near-infrared spectroscopy (NIRS) is a non-invasive optical technique for monitoring hemodynamic changes related to cortical neural activity by measuring relative changes in haemoglobin (Hb). Previous NIRS studies have reported functional abnormalities in the prefrontal cortex during a cognitive task in patients with SZ and BD-I (mainly individuals with bipolar II disorder). Recent studies have also reported that, compared with...
Patients with SZ demonstrated longer SSRTs than HCs (P = 0.011; Table 1). No significant differences were observed between patients with BD-I and HCs (P = 0.30) or between the SZ and BD-I groups (P = 0.30).

HCs, individuals with SZ show functional abnormalities of the bilateral prefrontal cortex during Go/No Go22 and stop-signal tasks23. Additionally, patients with bipolar II disorder show decreased oxygenated haemoglobin (oxy-Hb) changes in the bilateral orbitofrontal and left prefrontal cortices during the Iowa Gambling Task 24.

In the current study, we investigated differences in cortical frontotemporal functional abnormalities associated with inhibitory control between patients with SZ or BD-I and HCs. We hypothesised that patients with SZ or BD-I possess shared—as well as different—cortical function patterns. These functional abnormalities appear to be directly associated with observed cognitive and clinical features, and these associations may characterise important differences in psychopathology between the two disorders.

Results
Demographic characteristics. The study participants consisted of patients with SZ (n = 20), BD-I (n = 21) and 18 HCs. Participants’ demographic data are shown in Table 1.

Task performance. SSRTs differed significantly across the SZ, BD-I and HC groups (P = 0.015; Table 1). Patients with SZ demonstrated longer SSRTs than HCs (P = 0.011). No significant differences were observed between patients with BD-I and HCs (P = 0.26) or between patients with SZ and BD-I (P = 0.30).

Cognitive activation within groups. HCs showed significantly increased mean oxy-Hb levels between the pre-task baseline and the inhibitory control task period in 45 of 52 channels (ch1–5, ch8–9, ch11–16, ch18–20, ch22–30, ch32–41 and ch43–52; t = −8.27 to −2.28; maximum false discovery rate (FDR)-corrected P < 0.05, corrected for 52 channels). Thus, widespread frontotemporal cortical activation related to oxy-Hb was induced by the inhibitory control task in HCs. Patients with SZ showed significantly increased mean oxy-Hb levels in 14 of 52 channels (ch19, ch29–30, ch34–36, ch38–39, ch44–47 and ch49–50; t = −4.22 to −2.76; FDR-corrected P < 0.05, corrected for 52 channels). By contrast, patients with BD-I did not show significant changes in oxy-Hb levels in any channel (FDR-corrected P < 0.05, corrected for 52 channels). Figure 1 summarises the cognitive activation results for all three groups.

| SZ | BD-I | HC | Statistics | P-value |
|----|------|----|------------|---------|
| N  | %    | N  | %          |         |
| Female, n (%) | 11  | 55.0% | 12  | 57.1% | 10  | 55.6% | X² = 0.02 | 0.990 |
| Medication class, n (%) | | | | | | | | |
| Antipsychotics | 19  | 95.0% | 9   | 42.9% | X² = 12.9 | 0.000 |
| Mood stabilisers | 4   | 20.0% | 12  | 57.1% | X² = 5.9  | 0.015 |
| Antidepressants | 6   | 30.0% | 8   | 38.1% | X² = 0.3  | 0.585 |
| Mean SD | Mean SD | Mean SD | Mean SD | Statistics | P-value |
| Age, years | 33.6 | 8.7  | 36.9 | 10.2 | 36.6 | 10.7 | F(df = 2.56) = 0.70 | 0.505 |
| Education, years | 13.7 | 2.7  | 13.3 | 2.7  | 14.4 | 1.6  | F(df = 2.56) = 1.1  | 0.347 |
| Premorbid IQ* | 103.3 | 9.3  | 105.4 | 7.9  | 106.3 | 9.9  | F(df = 2.53) = 0.5  | 0.599 |
| Handedness | 93.0 | 11.7 | 77.1 | 40.6 | 87.2 | 17.4 | F(df = 2.56) = 1.8  | 0.172 |
| Duration of illness | 9.2 | 4.8  | 10.4 | 7.3  | F(df = 39) = 0.6  | 0.529 |
| Antipsychotic dosage | 498.1 | 446.1 | 126.2 | 183.7 |
| Antidepressant dosage | 28.5 | 54.6 | 40.8 | 77.0 |
| GAF scores | 49.6 | 16.3 | 52.8 | 16.2 | \(t(df = 39) = 0.6\) | 0.536 |
| HAMD | 10.3 | 7.3  | \(t(df = 39) = 0.6\) | 0.000 |
| YMRS | 2.5  | 2.6  | \(t(df = 39) = 0.6\) | 0.568 |
| PANSS scores | \(t(df = 39) = 4.3\) | 0.000 |
| Total | 15.4 | 5.1  | 9.0  | 4.2  | \(t(df = 39) = 4.3\) | 0.000 |
| Positive | 18.6 | 4.1  | 9.4  | 3.3  | \(t(df = 39) = 7.8\) | 0.000 |
| Negative | 36.8 | 7.6  | 29.4 | 8.5  | \(t(df = 39) = 2.9\) | 0.006 |
| General | 70.8 | 15.2 | 47.8 | 14.1 | \(t(df = 39) = 5.0\) | 0.000 |
| Task performance | | | | | | | | |
| Stop-signal delay | 400.3 | 152.2 | 433.4 | 148.7 | 437.4 | 147.4 | F(df = 2.56) = 0.36 | 0.70 |
| Stop-signal reaction time | 366.7 | 53.7 | 335.8 | 83.0 | 302.5 | 54.0 | F(df = 2.56) = 4.5 | 0.015 |
| Percentage of miss trials | 2.7  | 4.0  | 3.7  | 9.6  | 0.9  | 1.5  | F(df = 2.56) = 0.99 | 0.38 |

Table 1. Participant demographics and clinical characteristics. SZ, schizophrenia; BD-I, bipolar I disorder; GAF, Global Assessment of Functioning scale; HC, healthy control; PANSS; Positive and Negative Syndrome Scale. *Data were missing for two patients with SZ and one with BD-I. †Analysed using Mann–Whitney U test. ‡Patients with SZ demonstrated longer SSRTs than HCs (P = 0.011); no significant differences were observed between patients with BD-I and HCs (P = 0.26) or between the SZ and BD-I groups (P = 0.30).
Regional differences in task-related oxy-Hb changes among groups. Task-related oxy-Hb changes differed significantly among the SZ, BD-I and HC groups in 21 channels (ch4–5, ch12, ch14–15, ch18, ch24–25, ch34–37, ch39, ch43–46, ch48–51; F = 4.23–11.18; FDR-corrected P < 0.05, corrected for 52 channels). Compared with HCs, the SZ group exhibited significantly smaller task-related oxy-Hb changes in 11 channels (ch5, ch14–15, ch18, ch25, ch36–37, ch39, ch46 and ch48–49; p = 0.009–0.049), whereas the BD group exhibited significantly smaller changes in 21 channels (ch4–5, ch12, ch14–15, ch18, ch24–25, ch34–37, ch39, ch43–46 and ch48–51; P = 0.000–0.044; Fig. 2). Thus, both patient groups produced significantly smaller task-related changes in oxy-Hb levels in the bilateral middle frontal, inferior frontal and superior frontal gyri compared with HCs (Table 2). Furthermore, patients with BD-I demonstrated significantly smaller task-related changes in oxy-Hb levels in the bilateral middle frontal, inferior frontal and superior frontal gyri compared with HCs.

Figure 1. P-value significance map of cognitive activation among patients with SZ or BD-I and HCs (false discovery rate [FDR]-corrected P < 0.05, corrected with 52 channels). Blue-coloured circles represent significantly increased mean oxy-Hb changes from pre-task baseline to the inhibitory control task period in schizophrenia, bipolar I disorder and healthy controls. Channels that showed no significant correlations are highlighted in grey.
levels than patients with SZ or HCs in three channels (ch43–45; P = 0.015–0.036) located in the middle temporal and superior temporal gyri.

In addition, analysis of covariance (ANCOVA) revealed that task-related oxy-Hb changes differed significantly among the SZ, BD-I and HC groups in 9 channels (ch5, ch34–35, ch43–46, ch49 and ch51; F = 5.41–11.59; FDR-corrected P < 0.05, corrected for 52 channels). The BD group exhibited significantly smaller task-related oxy-Hb changes in 9 channels in comparison to HCs (ch5, ch34–35, ch43–46, ch49 and ch51; P = 0.000–0.010) and in 3 channels in comparison to the SZ group (ch43–45; P = 0.004–0.021). However, ANCOVA did not show any significance between the SZ and HC groups after FDR correction.

Figure 3 summarises the results of regional differences in task-related changes in oxy-Hb levels in patients with SZ or BD-I. In brief, reduced hemodynamic responses in the bilateral middle frontal, inferior frontal and superior frontal (including orbitofrontal region) gyri are a shared feature in SZ and BD-I. However, the reduction in the right superior temporal gyrus is specific to patients with BD-I.

Correlation analysis. Significant negative correlations between individual SSRT and task-related oxy-Hb changes were observed in the SZ group at four channels (ch36 and ch46–48; r = −0.71 to −0.64; FDR-corrected P < 0.05, corrected for 52 channels) located in the right middle frontal, inferior frontal and left superior frontal gyrus, as well as in the BD-I group at one channel (ch45; r = −0.70; FDR-corrected P < 0.05, corrected for 52 channels) located in the right inferior frontal gyrus. There were no significant correlations between SSRT and task-related oxy-Hb changes in HCs. Figure 4 summarises the correlation analysis in patients with SZ or BD-I.

We observed significant negative correlations between the Global Assessment of Functioning (GAF) scale score and task-related oxy-Hb changes in the BD-I group at two channels (ch43–44; r = −0.72 to −0.68; FDR-corrected P < 0.05, corrected for 52 channels) located in the right middle and superior temporal gyri. No significant correlations were observed between task-related oxy-Hb changes and any other clinical variable in the SZ, BD-I, or HC groups, including antipsychotic or antidepressant dosage. No significant correlations were observed between task-related oxy-Hb changes and HAMD or YMRS scores in the BD-I group.
### Table 2. Regional differences in task-related oxy-Hb changes among SZ, BD-I and HC groups. Abbreviations: SZ, schizophrenia; BD-I, bipolar I disorder; HC, healthy control.

| Region                        | R/L | NIRS CH | Mean oxy-Hb changes | HC   | F-value | Post hoc (P-value) |
|-------------------------------|-----|---------|----------------------|------|---------|--------------------|
|                               |     |         | SZ                    | BD-I |         | SZ vs. HC | BD-I vs. HC | SZ vs. BD-I |
| Postcentral gyrus R           | ch12| 0.038   | 0.025 ± 0.114         | 0.119± 0.092 | 5.72    | 0.019     | 0.008 | 0.954 |
| Superior temporal gyrus L     | ch51| 0.099   | 0.011 ± 0.092         | 0.056± 0.102 | 5.20    | 0.019     | 0.018 | 1.000 |
| Middle temporal gyrus R       | ch43| 0.104   | 0.030 ± 0.106         | 0.135± 0.082 | 6.07    | 0.009     | 0.009 | 0.999 |
| Superior temporal gyrus R     | ch44| 0.128   | 0.051 ± 0.069         | 0.151± 0.138 | 4.62    | 0.049     | 0.016 | 0.890 |
| Inferior frontal gyrus R      | ch45| 0.120   | 0.021 ± 0.055         | 0.111± 0.116 | 4.62    | 0.017     | 0.044 | 0.906 |
| Middle frontal gyrus R        | ch14| 0.011   | 0.057 ± 0.097         | 0.152± 0.107 | 6.52    | 0.020     | 0.003 | 0.791 |
| Inferior frontal gyrus L      | ch39| 0.025   | 0.167 ± 0.130         | 0.177± 0.130 | 6.10    | 0.019     | 0.005 | 0.857 |
| Superior frontal gyrus R      | ch5  | 0.078   | 0.025 ± 0.0130        | 0.167± 0.115 | 4.71    | 0.020     | 0.034 | 0.980 |
| Postcentral gyrus L           | ch50| 0.099   | 0.163 ± 0.162         | 0.152± 0.107 | 6.52    | 0.020     | 0.003 | 0.791 |
| Superior temporal gyrus R     | ch51| 0.014   | 0.025 ± 0.0130        | 0.152± 0.107 | 6.52    | 0.020     | 0.003 | 0.791 |
| BD-I < HC                     |     |         | 0.043 ± 0.096         | 0.107± 0.116 | 5.18    | 0.012     | 0.066 | 0.416 |

### Discussion

To our knowledge, this is the first NIRS study to directly compare regional cortical hemodynamic responses associated with inhibitory control among patients with SZ or BD-I and HCs. Patients with SZ or BD-I exhibited functional abnormalities associated with inhibitory control in the right inferior frontal gyrus. The differential abnormalities associated with behavioural inhibition were observed in the right middle and superior frontal gyri in patients with SZ and in the right superior temporal gyrus of patients with BD-I. Our findings suggest that differential patterns of frontotemporal functional abnormalities may reflect an important difference in psychopathology between schizophrenia and bipolar disorder.

Compared with HCs, patients with SZ or BD-I showed significantly reduced hemodynamic responses in the bilateral inferior frontal, middle frontal and superior frontal gyri. These results are consistent with previous SZ or BD-I neuroimaging studies that reported functional abnormalities in these regions7,12–16. The right inferior frontal gyrus is known to play a general role in attentional control, rapidly adapting inhibitory control responses to current salient stimuli35–37. Previous neuroimaging studies of HCs reported activation of the right inferior frontal and superior temporal gyri during a response inhibition task26. By contrast, studies have reported significant associations between poor inhibitory control and the volume of damage to grey matter in the right inferior frontal gyrus in patients with lesions of the right frontal lobe38 and reduced white matter fractional anisotropy in this region in patients with methamphetamine dependence28. Our results indicate that poor inhibitory control is associated with reduced hemodynamic responses in the right inferior frontal gyrus of patients with SZ or BD-I. These individuals have specific patterns of cerebral alterations in the right inferior frontal gyrus; this region may therefore be a neural substrate of impaired behavioural inhibition. Our findings suggest that right inferior frontal abnormalities mediate deficits in inhibitory control that are shared across patients with either SZ or BD-I.

In addition, the results of the current study suggest that patients with SZ exhibited deficits in inhibitory control associated with reduced hemodynamic responses in the right middle frontal and left superior frontal gyri, including the orbitofrontal region (channels 47–48). Previous studies on individuals with SZ indicated that structural or functional abnormalities in the orbitofrontal cortex were strongly associated with impulsive aggression or suicidal behavior31–33. Furthermore, alterations of orbitofrontal areas associated with SZ have been linked to positive and negative symptom profiles in previous structural neuroimaging studies34,35. Taken together, these studies suggest that functional abnormalities in the orbitofrontal region impair inhibition during impulsive or aggressive expression of symptoms in patients with SZ. Further, the alteration in this region may be related to the specific psychopathology of SZ. Our findings suggest that orbitofrontal functional abnormalities related to impaired behavioural inhibition are a neural substrate of the impulsive or aggressive clinical features associated with SZ.
Figure 3. Shared or differential functional abnormalities in patients with SZ or BD-I compared with HCs. (A) Brain areas in green indicate regions with reduced hemodynamic responses, compared with HCs, overlapped in both patients with SZ and BD-I: bilateral inferior frontal, middle frontal and superior frontal (including orbitofrontal region) gyri. (B) Dot plots of task-related oxy-Hb changes in the right inferior frontal gyrus (channel 46) in the SZ, BD-I and HC groups. (C) Differential time course of task-related oxy-Hb signals in the SZ, BD-I and HC groups in the right inferior frontal gyrus (channel 46). In the HC group, the time course of changes in the task-related oxy-Hb signal showed a gradual increase; the SZ and BD-I groups did not exhibit this response. (D) Brain areas in blue indicate regions where reduced hemodynamic responses, compared with SZ and HC subjects, were observed in BD-I: right inferior frontal and superior temporal gyri. (E) Dot plots of task-related oxy-Hb changes in the superior temporal gyrus (channel 44) in the SZ, BD-I and HC groups. (F) Differential time course of task-related oxy-Hb signal in the SZ, BD-I and HC groups in the right superior temporal gyrus (channel 44). In the SZ and HC groups, the time course of changes in the task-related oxy-Hb signal showed a rapid increase; the BD-I group did not exhibit this response.
By contrast, patients with BD-I demonstrated reduced hemodynamic responses in the right superior temporal gyrus, which was unique to this group. Moreover, patients with BD-I exhibited negative associations between SSRT and hemodynamic responses in this region. The superior temporal cortex (gyrus and sulcus) is part of a complex face-processing system involved in the perception of emotions and regulating responses to negative visual social stimuli. Recent structural neuroimaging studies in patients with BD-I have found abnormally reduced thickness of the right superior temporal cortex or abnormally reduced fractional anisotropy in the right temporal lobe. One investigation suggested that reduced activation in the superior temporal sulcus may indicate disturbances in affect-processing circuitry, leading to abnormalities in mood and social cognition. These findings suggest that the superior temporal gyrus is an important neural substrate of emotion regulation and reward processing, and that alterations in this region may produce some of the cognitive symptoms and social impairments associated with BD-I. Moreover, functional abnormalities in this region may result in impaired emotional control inhibition in individuals with BD-I. This hypothesis is partly supported by the results of the current study, which showed an association between impaired global functioning and abnormal right temporal region hemodynamic responses in patients with BD-I. Our findings suggest that the functional abnormalities related to inhibitory control in the right superior temporal gyrus are characteristic of BD-I.

In addition, patients with SZ showed significantly longer SSRTs compared to patients with BD-I or HCs. This is consistent with previous evidence associating SZ with response inhibition deficits. An alternative explanation for this difference between SZ and BD-I groups is that the current mood state in patients with BD-I influenced SSRT, whereas the deficits persisted across all phases of BD-I. A further explanation is that neuroimaging techniques, including the NIRS signal, are more sensitive than SSRT at detecting differences between the BD-I and HC groups, especially given small sample sizes. In the current study, we considered observed differences in hemodynamic responses among patients with SZ or BD-I and HCs to be activated by the stop-signal task.

There are several potential limitations to our study. First, our sample size was small, which may have limited the statistical power to produce reliable findings, i.e. ANCOVA did not show any significant differences between the SZ and HC groups after FDR correction. This could also explain why associations between SSRT and task-related oxy-Hb changes were not observed in HCs. In addition, the NIRS signal might be more sensitive, allowing greater detection of cortical functional abnormalities in patients with psychiatric diagnoses. This speculation is partly supported by previous NIRS studies that did not detect brain regions associated with task.

Figure 4. Shared or differential functional abnormalities associated with SSRT in patients with SZ or BD-I. (A) Brain areas in red indicate regions where task-related oxy-Hb changes negatively correlated with SSRT in the SZ group, and brain areas in blue indicate regions where task-related oxy-Hb changes negatively correlated with SSRT in the BD-I group. (B) Scatter plots showing the relationship between SSRT and task-related oxy-Hb changes in channels 45 and 46 (right inferior frontal gyrus) and 48 (right superior frontal gyrus).
performances in HCs during Go/No Go and stop-signal tasks. Further studies with larger sample sizes are needed to verify our findings. Second, we cannot exclude the possibility of medication effects on hemodynamic responses in patients with SZ and BD-I. However, it should be noted that the dosage of antidepressants or antipsychotics was not correlated with hemodynamic responses in any channels, suggesting a minimal confounding effect of medication. In addition, previous NIRS studies have reported no significant effect of psychotropic medications on neural activity in patients with SZ or BD. Lastly, NIRS has lower spatial resolution to detect cortical activity from the scalp surface than other neuroimaging techniques such as fMRI. However, this limitation should be within an acceptable range because differences in hemodynamic responses in patients with SZ or BD-I and HCs were clearly observed in our study, as they have been in other NIRS studies. In addition, we used a virtual spatial registration method to define the spatial information for each channel using data. This method was used in most recent NIRS studies and may be useful for replicating our findings.

Conclusion
This study demonstrated shared and differential patterns of hemodynamic responses in the frontotemporal cortex among patients with SZ or BD-I and HCs. Our findings suggest that differential patterns in frontotemporal functional abnormalities may reflect important differences in the psychopathological features of SZ or BD-I. NIRS is a non-invasive neuroimaging modality with easy applicability and high ecological validity. This makes NIRS particularly suitable for use with patients with psychiatric diagnoses who may be afraid of enclosed spaces or exhibit motor restlessness that interferes with motion-sensitive imaging methods. Therefore, NIRS has the potential to be a powerful and specific diagnostic tool for use among individuals with SZ or BD-I.

Methods
Participants. The diagnosis of SZ or BD-I was made according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria using the Mini International Neuropsychiatric Interview (MINI). HCs were also screened using the MINI and excluded if there was any history of psychiatric disorders or heritable neurological diseases among first- or second-order relatives. Exclusion criteria for the study groups were as follows: a history of head trauma with loss of consciousness for more than 5 min, current or previous neurological disease, current or previous endocrine disease, a history of electroconvulsive therapy and/or alcohol/substance abuse or addiction.

Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Depression severity was evaluated using the 17-item Hamilton depression rating scale administered using a structured interview guide. Manic symptoms were assessed using the Young mania rating scale (YMRS). Premorbid IQ was estimated using the Japanese version of the National Adult Reading Test. Handedness was evaluated according to the Edinburgh Inventory. The chlorpromazine-equivalent dose of antipsychotics was calculated for each patient.

After providing a complete description of the study, written informed consent was obtained from all participants. This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Kindai University Faculty of Medicine. All data generated or analysed during this study are included in this article.

NIRS methodology. We used a 52-channel NIRS device (ETG-4000 Optical Topography System; Hitachi Medical Co., Tokyo, Japan) to measure relative changes in oxy-Hb and deoxygenated haemoglobin (deoxy-Hb) at two wavelengths (694 and 830 nm) of near-infrared light (indicated as mM) based on the modified Beer-Lambert law. The NIRS probes were fixed using 3 × 11 thermoplastic shells with 17 emitters and 16 detectors.
The distance between each source and detector probe was 30 mm and the area analysed between the probes was defined as a 'channel'. The probes of the NIRS device were placed on the frontotemporal region of each participant, with the lowermost probes located along the T3-Fp1-Fpz-Fp2-T4 line, in accordance with the International 10–20 Placement System used for electroencephalography. The NIRS device can measure Hb values bilaterally from the prefrontal and temporal surface regions at depths of 20–30 mm from the scalp, which correspond with the surface of the cerebral cortex. The spatial information for each channel was estimated using data from the Functional Brain Science Laboratory at Jichi Medical University, Japan45,46. According to the LONI Probabilistic Brain Atlas (LPBA40) 47, NIRS channels can record functional hemodynamics within the bilateral frontal, temporal and parietal cortices. We anatomically labelled NIRS channels only after the LPBA40 region of highest probability was determined (Fig. 5).

We recorded relative mean changes in Hb concentrations from baseline in mM because NIRS cannot measure the absolute path length from the emitter to the detector. NIRS signals were acquired with a time resolution of 0.1 s. We set the moving average window to 5 s to remove high frequency noise such as heartbeat and small bodily movements. Channel records with low signal-to-noise ratios or motion artefacts were excluded, and there was no difference in the number of samples at each channel, including the channels that indicated significant differences among study groups.

In the present study, we focused on changes in oxy-Hb. Animal studies indicate that oxy-Hb is the most sensitive indicator of regional cerebral blood flow because the direction of change in deoxy-Hb is determined by the degree of change in venous blood oxygenation and volume57. Pre-task baseline was determined as the mean across the last 10 s of the 30 s pre-task segment. The obtained oxy-Hb data were averaged for each participant during each baseline and task period. The task-related oxy-Hb changes (task minus baseline) were used for statistical analysis.

**Stop-signal task.** We used a variation on the classic stop-signal task4 (SST) to assess inhibitory control58. The original task design has been described in detail58,59. In brief, across the task period, participants viewed the shape of a 'go' stimulus (circle or square) that appeared on screen in rapid succession. Occasionally, an auditory stop signal was presented at a short, variable delay after the onset of the go stimulus.

**Procedure.** The cognitive activation task used in this study had a one-block design and included 1) a pre-task baseline period and 2) a stop-signal task period (Fig. 6A). During a 30 s pre-task period, participants were instructed to alternatively tap with their right and left index fingers every 1 s as accurately as they could. (B) During the stop-signal task, subjects were instructed to respond as quickly and accurately as possible to the go stimulus (●, ■) in no-stop-signal trials. In stop-signal trials, participants were instructed to try to withhold their response as required until the auditory stop signal occurred.

Figure 6. Task segments in the NIRS measurements and depiction of a trial in the stop-signal paradigm. (A) Overall task period. During the pre-task period, subjects were instructed to alternatively tap with their right and left index fingers every 1 s as accurately as they could. (B) During the stop-signal task, subjects were instructed to respond as quickly and accurately as possible to the go stimulus (●, ■) in no-stop-signal trials. In stop-signal trials, participants were instructed to try to withhold their response as required until the auditory stop signal occurred.
the left and right buttons on a keyboard. The task consisted of a block of 64 trials; stop-signal trials (75% of trials) and non-stop-signal trials (25% of trials) were randomly presented. Each trial started with the presentation of a fixation sign on a computer monitor, which was replaced by the primary task stimulus after 250 ms. Stop-signal delay was initially set at 250 ms and continuously adjusted with the staircase tracking procedure (range of 250–1050 ms). When inhibition was successful, the stop-signal delay increased by 50 ms; when inhibition was unsuccessful, it decreased by 50 ms. Response registration continued during stop-signal presentation. In stop-signal trials, the go stimulus was followed by a stop signal (75 Hz, 75 ms) after a variable stop-signal delay. In both no-stop-signal trials and stop-signal trials, the go stimulus remained on screen until subjects responded or the maximal reaction time (RT: 1,250 ms) had elapsed. The inter-trial interval was 2,000 ms and independent of RT. Participants were instructed to respond as quickly and accurately as possible to the go stimulus in non-stop-signal trials. In stop-signal trials, participants were instructed to try to withhold their response as required until the auditory stop signal occurred (Fig. 6B).

**Statistical analysis.** Demographic and clinical variables were compared among the study groups using the χ² test, t-test and one-way ANOVA followed by Tukey’s post hoc test. Statistical significance was assumed at P < 0.05 (two-tailed).

To identify regional differences in frontotemporal hemodynamic activation associated with the inhibitory control task, we compared mean oxy-Hb changes during the pre-task (baseline) and task periods for every channel within individual subjects using the paired t-test. Task-related oxy-Hb changes were compared among the study groups using ANOVA followed by Tukey’s post hoc test. Because Tukey’s post hoc test focused on NIRS channels where the hemodynamic response was shown to be significant after FDR correction, no further correction for multiple comparisons was applied for the post hoc test and responses were considered significant at P < 0.05. Complementary analyses were performed to identify between-group differences in activation associated with inhibitory control using ANCOVA with age, gender (dummy parameterised, male = 0, female = 1) and SSRT as covariates. Furthermore, to examine the relationships between task-related oxy-Hb changes and clinical variables, we calculated Pearson’s correlation coefficients. We set the value of q (i.e. FDR) to 0.05 such that the false-positive rate was not greater than 5% on average when processing oxy-Hb data obtained from multiple channels.

**References**

1. Craddock, N. & Sklar, P. Genetics of bipolar disorder. *Lancet* **381**, 1654–1662, https://doi.org/10.1016/s0140-6736(13)60855-7 (2013).
2. Barch, D. M., Braver, T. S., Carter, C. S., Poldrack, R. A. & Robbins, T. W. CNTRICS final task selection: executive control. *Schizophr. Bull.* **35**, 115–135, https://doi.org/10.1093/schbul/bdn154 (2009).
3. Banich, M. T. & Depue, B. E. Recent advances in understanding neural systems that support inhibitory control. *Curr. Opin. Behav. Sci.* **1**, 17–22, https://doi.org/10.1016/j.cobeha.2014.07.006 (2015).
4. Logan, G. D. & Cowan, W. B. On the ability to inhibit thought and action: A theory of an act of control. *Psychol. Rev.* **91**, 295–327, https://doi.org/10.1037/0033-295X.91.3.295 (1984).
5. Lipszyc, J. & Schachar, R. Inhibitory control and psychopathology: a meta-analysis of studies using the stop signal task. *J. Int. Neuropsychol. Soc.* **16**, 1064–1076, https://doi.org/10.1017/S1355617710000895 (2010).
6. Ethridge, L. E. *et al.* Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to general cognitive deficit. *Schizophr. Res.* **159**, 491–498, https://doi.org/10.1016/j.schres.2014.08.025 (2014).
7. Hajek, T., Alda, M., Hajek, E. & Ivanoff, J. Functional neuroanatomy of response inhibition in bipolar disorders—combined voxel based and cognitive performance meta-analysis. *J. Psychiatr. Res.* **47**, 1955–1966, https://doi.org/10.1016/j.jpsychires.2013.08.015 (2013).
8. Hampshire, A., Chamberlain, S. R., Monti, M. M., Duncan, J. & Owen, A. M. The role of the right inferior frontal gyrus: inhibition and attentional control. *Neuroimage* **50**, 1313–1319, https://doi.org/10.1016/j.neuroimage.2009.12.109 (2010).
9. Sharp, D. J. *et al.* Distinct frontal systems for response inhibition, attentional capture, and error processing. *Proc. Natl. Acad. Sci. USA* **107**, 6106–6111, https://doi.org/10.1073/pnas.1001751107 (2010).
10. Wagner, T. D. *et al.* Common and unique components of response inhibition revealed by fMRI. *Neuroimage* **27**, 323–340, https://doi.org/10.1016/j.neuroimage.2005.05.054 (2005).
11. Aron, A. R., Poldrack, R. A. Cortical and subcortical contributions to stop signal response inhibition: role of the subthalamic nucleus. *J. Neurosci.* **25**, 2424–2433, https://doi.org/10.1523/JNEUROSCI.4682-05.2006 (2006).
12. Minzenberg, M. J., Laird, A. R., Thelen, S., Carter, C. S. & Glahn, D. C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. *Arch. Gen. Psychiatry* **66**, 811–822, https://doi.org/10.1001/archgenpsychiatry.2009.91 (2009).
13. Zandbelt, B. B., van Buuren, M., Kahn, R. S. & Vink, M. Reduced proactive inhibition in schizophrenia is related to corticostriatal dysfunction and poor working memory. * Biol. Psychiatry* **70**, 1151–1158, https://doi.org/10.1016/j.biopsycho.2011.07.028 (2011).
14. Hughes, M. E., Fulham, W. R., Johnston, P. J. & Michie, P. T. Stop-signal response inhibition in schizophrenia: behavioural, event-related potential and functional neuroimaging data. *Biol. Psychol.* **89**, 220–231, https://doi.org/10.1016/j.biopsycho.2011.10.013 (2012).
15. Hanford, L. C., Nazarov, A., Hall, G. B. & Sassi, R. B. Cortical thickness in bipolar disorder: a systematic review. *Bipolar Disord.* **18**, 4–18, https://doi.org/10.1111/bdi.12362 (2016).
16. Pigeau, C., Fodoulian, L., Aubry, J. M., Vulemeyer, P. & Houenou, J. Bipolar disorder: Functional neuroimaging markers in relatives. *Neurosci. Biobehav. Rev.* **37**, 284–296, https://doi.org/10.1016/j.neubiorev.2015.08.015 (2015).
17. Weathers, J. D. *et al.* A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder. *Am. J. Psychiatry* **169**, 635–641, https://doi.org/10.1176/appi.ajp.2012.11081244 (2012).
18. Strakowski, S. M. *et al.* Magnetic resonance imaging brain activation in first-episode bipolar mania during a response inhibition task, *Early Interv. Psychiatry* **2**, 225–233, https://doi.org/10.1111/1751-7893.2008.00082.x (2008).
19. Marumo, K. *et al.* Functional abnormalities in the left ventrolateral prefrontal cortex during a semantic fluency task, and their association with thought disorder in patients with schizophrenia. *Neuroimage* **85**(Pt 1), 518–526, https://doi.org/10.1016/j.neuroimage.2013.04.050 (2014).
20. Takizawa, R. *et al.* Reduced frontopolar activation during verbal fluency task in schizophrenia: a multi-channel near-infrared spectroscopy study. *Schizophr. Res.* **99**, 250–262, https://doi.org/10.1016/j.schres.2007.10.025 (2008).
21. Kameyama, M. *et al.* Frontal lobe function in bipolar disorder: a multichannel near-infrared spectroscopy study. *Neuroimage* **29**, 172–184, https://doi.org/10.1016/j.neuroimage.2005.07.025 (2006).
22. Nishimura, Y. et al. Prefrontal cortex activity during response inhibition associated with excitement symptoms in schizophrenia. *Brain Res.* 1370, 194–203, https://doi.org/10.1016/j.brainres.2010.11.003 (2011).

23. Okada, N. et al. Characterizing prefrontal cortical activity during inhibition task in methamphetamine-associated psychosis versus schizophrenia: a multi-channel near-infrared spectroscopy study. *Addict. Biol.* 21, 489–503, https://doi.org/10.1111/adb.12224 (2016).

24. Ono, Y. et al. Reduced prefrontal activation during performance of the Iowa Gambling Task in patients with bipolar disorder. *Psychiatry Res.* 233, 1–8, https://doi.org/10.1016/j.psychres.2015.04.003 (2015).

25. Dehaene, S., Kerszberg, M. & Changeux, J. P. A neuronal model of a global workspace in effortful cognitive tasks. *Proc. Natl. Acad. Sci. USA* 95, 14529–14534 (1998).

26. Duncan, J. An adaptive coding model of neural function in prefrontal cortex. *Nature Reviews Neuroscience* 2, 820–829, https://doi.org/10.1038/35097557 (2001).

27. Corbetta, M. & Shulman, G. L. Control of goal-directed and stimulus-driven attention in the brain. *Nat. Rev. Neurosci.* 3, 201–215, https://doi.org/10.1038/nrn755 (2002).

28. Horn, N. R., Dolan, M., Elliott, R., Deakin, J. F. W. & Woodruff, P. W. R. Response inhibition and impulsivity: an fMRI study. *Neuropsychologia* 41, 1959–1966, https://doi.org/10.1016/j.neuropsychologia.2003.03.007 (2003).

29. Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J. & Robbins, T. W. Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. *Nat. Neurosci.* 6, 113–116, https://doi.org/10.1038/nn1003 (2003).

30. Buchheim, A. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. *Am. J. Psychiatry* 160, 572–574, https://doi.org/10.1176/appi.ajp.160.3.572 (2003).

31. Campbell, R., Heywood, C. A., Cowey, A., Regard, M. & Landis, T. Sensitivity to eye gaze in prosopagnosic patients and monkeys with superior temporal sulcus ablation. *Neuropsychologia* 38, 1123–1142 (1999).

32. Soyka, M. Neurobiology of aggression and violence in schizophrenia. *Psychiatry Clin. Neurosci.* 59, 18–25 (2014).

33. Mahon, K. et al. Abnormal temporal lobe white matter as a biomarker for genetic risk of bipolar disorder. * Biol. Psychiatry 73, 177–182, https://doi.org/10.1016/j.biopsych.2012.07.033 (2013).

34. Pavuluri, M. N., O’Connor, M. M., Harral, E. & Sweeney, J. A. Affective neural circuitry during facial emotion processing in pediatric bipolar disorder. *Psychiatry Res.* 62, 158–167, https://doi.org/10.1016/j.psychres.2006.07.011 (2007).

35. Hill, S. K. et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar- Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. * Am. J. Psychiatry* 170, 1275–1284, https://doi.org/10.1176/appi.ajp.2013.12101298 (2013).

36. Barrett, S. L., Mulholland, C. C., Cooper, S. J. & Rushe, T. M. Patterns of neurocognitive impairment in first-episode bipolar disorder and schizophrenia. *Br. J. Psychiatry* 195, 67–72, https://doi.org/10.1192/bjp.bp.108.058474 (2009).

37. Malli, G. S. et al. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. *Bipolar Disord.* 9, 114–125, https://doi.org/10.1111/j.1399-5618.2007.00324.x (2007).

38. Yamasu, M. et al. Diffential patterns of blood oxygenation in the prefrontal cortex between patients with methamphetamine-induced psychosis and schizophrenia. *Sci. Rep.* 5, 12107, https://doi.org/10.1038/srep12107 (2015).

39. Singh, A. K., Okamoto, M., Dan, H., Jurcak, V. & Dan, I. Spatial registration of multichannel multi-subject fNIRS data to MNI space without MRI. *NeuroImage* 27, 842–851, https://doi.org/10.1016/j.neuroimage.2005.05.019 (2005).

40. Tsuzuki, D. et al. Virtual spatial registration of stand-alone fNIRS data to MNI space. *NeuroImage* 34, 1506–1518, https://doi.org/10.1016/j.neuroimage.2006.10.043 (2007).

41. Shattuck, D. W. et al. Construction of a 3D probabilistic atlas of human cortical structures. *NeuroImage* 39, 1064–1080, https://doi.org/10.1016/j.neuroimage.2007.09.031 (2008).

42. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th edn, (American Psychiatric Association, 1994).

43. Osobu, T. et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. *Psychiatry Clin. Neurosci.* 59, 517–526, https://doi.org/10.1111/j.1440-1819.2005.01408.x (2005).

44. Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANS) for schizophrenia. *Schizophr. Bull.* 13, 261–276 (1987).

45. Williams, J. A. A structured interview guide for the Hamilton Depression Rating Scale. *Arch. Gen. Psychiatry* 45, 742–747 (1988).

46. Young, R. C., Beggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: reliability, validity and sensitivity. *Br. J. Psychiatry* 133, 429–435 (1978).

47. Matsuoaka, K., Uno, M., Kasai, K., Koyama, K. & Kim, Y. Estimation of premorbid IQ in individuals with Alzheimer's disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test. *Psychiatry Clin. Neurosci.* 60, 332–339, https://doi.org/10.1111/j.1440-1819.2006.01510.x (2006).

48. Oldfield, R. C. The assessment and analysis of handedness: the Edinburgh inventory. *Neuropsychologia* 9, 97–113 (1971).

49. Inada, T. & Inagaki, A. Psychotropic dose equivalence in Japan. *Psychiatry Clin. Neurosci.* 69, 440–447, https://doi.org/10.1111/pcn.12275 (2015).

50. Cope, M. et al. Methods of quantitating cerebral near infrared spectroscopy data. *Adv. Exp. Med. Biol.* 222, 183–189 (1988).

51. Hoshi, Y., Kobayashi, N. & Tamura, M. Interpretation of near-infrared spectroscopy signals: a study with a newly developed perfused rat brain model. *J. Appl. Physiol.* 90, 1657–1662 (2001).

52. Verbruggen, F., Logan, G. D. & Stevens, M. A. STOP-IT: Windows executable software for the stop-signal paradigm. *Behav. Res. Methods* 40, 479–483, https://doi.org/10.3758/brm.40.2.479 (2008).

53. Buchheim, A. & Logan, G. D. Response inhibition in the stop-signal paradigm. *Trends Cogn. Sci.* 12, 418–424, https://doi.org/10.1016/j.tics.2008.07.005 (2008).

54. Singh, A. K. & Dan, I. Exploring the false discovery rate in multichannel NIRS. *NeuroImage* 33, 542–549, https://doi.org/10.1016/j.neuroimage.2006.06.047 (2006).
Acknowledgements
This work was partly supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (No. 25461792 and No. 16K10229).

Author Contributions
N.T. designed the study, wrote the protocol, collected the data, undertook the statistical analyses and wrote the manuscript. W.M. and T.A. collected the data. T.H. critically revised the text for important intellectual content. O.S. is the head of our laboratory and designed the study, wrote the protocol and was involved in working on all drafts of the manuscript. All authors contributed to and have approved the final manuscript.

Additional Information
Competing Interests: Dr. Shirakawa has received honoraria from Pfizer, GlaxoSmithKline and Eli Lilly. The other authors report no financial relationships with commercial interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018